Mulkins M A, Heidelberger C
Cancer Res. 1982 Mar;42(3):965-73.
Twenty clones stably resistant to 5-fluorouracil, 5-fluoro-2'-deoxyuridine, or 5-fluorouridine have been isolated from L1210 or P388 murine leukemia cells by a one-step mutation and selection procedure. The activities of enzymes of the pyrimidine salvage pathway relevant to the activation of these drugs have been determined in order to elucidate the mechanisms of resistance in these cells. Cell line resistant to 5-fluorouracil have 7 to 50% of the pyrimidine phosphoribosyltransferase activity found in the wild-type cells, with 5-fluorouracil, uracil, or orotate as substrate. Cells selected for resistance to 5-fluoro-2'-deoxyuridine have no detectable thymidine kinase activity. 5-Fluorouridine-resistant cells have 3 to 25% of the uridine kinase activity measured in the wild-type cell lines. No significant changes were observed in the activities of thymidylate synthetase, nucleoside phosphorylases, or 5-fluorouridylate kinase in any of the resistant cell lines. These findings have relevance to the treatment of human cancer, since pyrimidine phosphoribosyltransferase, thymidine kinase, or uridine kinase could be assayed in tumor biopsies in order to predict whether the fluoropyrimidines would be effective in individual patients.
通过一步突变和筛选程序,从L1210或P388小鼠白血病细胞中分离出了20个对5-氟尿嘧啶、5-氟-2'-脱氧尿苷或5-氟尿苷稳定耐药的克隆。已测定了与这些药物激活相关的嘧啶补救途径中酶的活性,以阐明这些细胞的耐药机制。对5-氟尿嘧啶耐药的细胞系,以5-氟尿嘧啶、尿嘧啶或乳清酸为底物时,其嘧啶磷酸核糖基转移酶活性为野生型细胞的7%至50%。选择对5-氟-2'-脱氧尿苷耐药的细胞没有可检测到的胸苷激酶活性。对5-氟尿苷耐药的细胞,其尿苷激酶活性为野生型细胞系所测活性的3%至25%。在任何耐药细胞系中,胸苷酸合成酶、核苷磷酸化酶或5-氟尿苷酸激酶的活性均未观察到显著变化。这些发现与人类癌症的治疗相关,因为可以在肿瘤活检中检测嘧啶磷酸核糖基转移酶、胸苷激酶或尿苷激酶,以预测氟嘧啶类药物对个体患者是否有效。